The Passage of the Harrison Narcotics Tax Act in 1914 was a landmark in the United States’ shift from medical use of opiates toward the restriction and criminalization of narcotics. It followed growing recognition that addiction could arise through medical treatment as well as recreational use; within a decade, heroin manufacture was outlawed, and people dependent on opioids were increasingly treated as criminals rather than patients. The book presents the law as part of a recurring history in which medical confidence in opioid drugs gives way to restriction, while the burdens of enforcement and access to care fall unevenly.

Medical Alarm and the Turn Toward Restriction

By the early twentieth century, physicians were warning that opioid dependence could follow ordinary pain treatment. In 1895, a Brooklyn doctor cautioned colleagues that leaving morphine and syringes with patients could lead to dependence after only a few doses, and argued that some cases could have been prevented by the initial prescription. By 1900, more than 250,000 Americans were addicted to opium-derived painkillers.

Heroin, meanwhile, had first been welcomed as a promising cough suppressant and promoted by Bayer as distinct from morphine. Although researchers raised concerns about its risks, it remained available in American drugstores and by mail order for eight years. In 1906, the American Medical Association issued a more forceful warning about the habit-forming potential of heroin. Hospital admissions related to heroin were rising in New York and Philadelphia in the 1910s and 1920s, and officials increasingly recognized addiction among both injured patients and recreational users. The law arrived amid this changing understanding: addiction was no longer easily confined to a supposedly separate world of vice.

Restrictions and Prohibition

The Harrison Narcotics Tax Act of 1914 severely restricted the sale and possession of heroin and other narcotic drugs. The measure became part of a broader turn toward prohibition, but the book distinguishes its passage from the subsequent outlawing of heroin manufacture: that prohibition came in 1924, twenty-six years after Bayer’s heroin pill first reached the market.

The change was not merely a change in the legal status of a drug. By the 1930s, heroin users were increasingly described as working-class people, including many children of immigrants, as well as jazz musicians and other creative workers. With legal supply curtailed and criminal networks becoming the means of obtaining heroin, dependence was recast through the language of crime. The book contrasts this population with the earlier, more socially respectable morphine and opium users, many of whom had been treated as patients. As that older group disappeared from public view, the remaining addicted people were identified as criminals rather than as people needing medical care.

A Long Afterlife in Drug Policy

The book links the national crackdown following the Harrison Act to the formation of drug prohibition and, later, the War on Drugs. In its account, this history also helps explain why opioid use could become culturally associated with distant urban settings even as earlier waves of medically caused addiction faded from public memory. In Roanoke, heroin was long treated as an inner-city drug and largely as a police and court matter; the small, mostly Black population of users and dealers was described as an isolated, largely invisible group. That history forms an important contrast with the later spread of prescription opioids into places where heroin had not been widely recognized as a local problem.

The Act’s legacy does not mean that later patterns of prescribing and enforcement were simply its direct effects. Rather, the book places the law within a repeated swing between medicalization and criminalization. In the 1990s, Purdue Pharma promoted OxyContin as suitable for a wide range of pain, while medical institutions were elevating pain as a vital sign and adopting mandatory standards for pain assessment and treatment. Pain scales made treatment easier to standardize, but the book notes that the measures could give a misleading appearance of objectivity and were associated with increased opioid prescribing and abuse. Meanwhile, federal rules on pharmaceutical advertising loosened and industry promotion expanded. The contrast is striking: narcotics had once been sharply restricted after addiction became visible, while a later medical and commercial system encouraged wider opioid use amid confident claims about safety.

Unequal Enforcement and the Public-Health Question

The later history described in the book shows that criminalization did not operate evenly. By the modern opioid crisis, white patients were prescribed painkillers at higher rates than people of color; 2014 data found that doctors’ mistrust of patients of color had limited their access to opioids. In the same period, overdose deaths among young white people had risen sharply compared with 2002, while the death rate for people of color had changed relatively little. The book places this disparity beside a different imbalance: people of color remained disproportionately represented among those imprisoned for drug offenses, even as public-health arguments against arrest were often directed toward white opioid users.

The Harrison Act therefore stands in the book not as a self-contained legislative episode, but as an early marker in a cycle whose consequences continue to be contested. Later responses described in the narrative include approaches that divert low-level drug offenders toward housing, employment support, and treatment rather than prosecution. That alternative underscores the central question raised by the Act’s long afterlife: whether addiction will be handled chiefly through punishment or through systems of care, and who will bear the cost of the choice.